Skip to content

Evaluation of Dexametasone supplementation for ovarian responsiveness in infertile women with polycystic ovaries in IVF (ICSI cycle)

Evaluation of Dexametasone supplementation for ovarian responsiveness in infertile women with polycystic ovaries in IVF (ICSI cycle)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201207031760N19
Enrollment
110
Registered
2012-11-19
Start date
2011-03-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovary syndrome

Interventions

Intervention 1: Intervention Group: 2 tablets of .5 Mg of dexamethasone (Daroupakhsh, Iran). Intervention 2: Control group : 400 micrograms of folic acid tablets (Natur Made / USA).
Treatment - Drugs
Placebo
Intervention Group: 2 tablets of .5 Mg of dexamethasone (Daroupakhsh, Iran)
Control group : 400 micrograms of folic acid tablets (Natur Made / USA)

Sponsors

Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: PCOs women with infertility duration less than 5 years; Age range 30-20 years. Exclusion criteria: Women with uterine problems such as Uterine fibroids and internal septa; Endometriosis; Women with a history of ovarian or ovarian surgery; The problem of male infertility.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy. Timepoint: The detection of fetal heartbeat, two weeks after being tested positive for HCG. Method of measurement: Ultrasound.

Secondary

MeasureTime frame
The number of embryos obtained. Timepoint: On the third day after the oocyte Removal. Method of measurement: Ultrasound.;Number of oocytes. Timepoint: 36-34 h after HCG injection. Method of measurement: Ultrasound.;Gonadotropin dose. Timepoint: The third day of the next menstrual cycle. Method of measurement: Clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNargess Gholizadeh Pasha

Fatemehzahra Fertility & reproductive Health Reseach Center

ngh_pa@yahoo.comzahra@mubabol.ac.ir+98 11 1227 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026